Christina Waters, Phd Mba Email and Phone Number
Christina Waters, Phd Mba work email
- Valid
- Valid
- Valid
- Valid
Christina Waters, Phd Mba personal email
- Valid
Christina Waters, Phd Mba phone numbers
Leveraging my international leadership experience and scientific knowledge, I build multidisciplinary teams to spearhead preclinical research, clinical development, and technology programs that achieve corporate objectives while positively impacting patients’ lives. I am passionate about using technology more effectively to address treatment access for patients with common, rare, neglected, and orphan diseases. By basing genomic and precision medicine approaches on diverse sets of data, I strive to promote equity among patients. As a C-level executive, I align science and business strategies, drive sustainable growth, and focus on my company’s vision for the future.I earned my Ph.D. in Genetics from UC-Davis as an NIH Biotechnology Fellow and was a Howard Hughes Fellow at CalTech. After my postdoc, I managed preclinical programs at Miravant, but it was Novartis that sparked my interest in orphan diseases and built my foundation in discovery research and clinical development. Working directly for the Head of Research and the Institute director I was responsible for moving drug discovery programs to Novartis across all disease areas. GNF grew to 300 medicinal chemistry, biology and engineers.Additional career accomplishments include:★ Orchestrated a brand-new revenue stream for Congenica that decreased risk of therapeutic development from discovery research to clinical development and post-market surveillance. ★ Led a multidisciplinary group for PMI that included large teams in Germany, Switzerland, and Singapore. My international experience also includes work in Italy, China, and the UK. ★ Built a startup, aTYR Pharma, from scratch (literally – there was no office or lab when I started).★ Created a nonprofit to address the inequities of access to knowledge and resources for children with rare disease; RARE Science is now 10 years old and represents around 1,000 diseases in 97 countries. ★ Navigated the Italian business landscape to spearhead structural changes for Cell Therapeutics.★ Mentored 3 female STEM graduate students. As a leader, I build high-performing teams and encourage growth and retention through coaching. My history includes leading global teams to optimize operational and scientific efficiency and achieve corporate goals. I am valuable in conducting due diligence for mergers, acquisitions, and in-licensing. I continue to use my skills and knowledge to support global health through genetics-driven prevention, diagnosis, and intervention.
Archer Precision Medicine Advisory Llc
View-
CeoArcher Precision Medicine Advisory Llc Jun 2019 - PresentAdvise client companies on business development, corporate strategy, and alignment of scientific strategies (build, buy, partner), consulting for life science organizations across the world.• Strategic consultant for UKRI Medical Research Council, Nucleic Acid Therapy Accelerator (Harwell, UK)• Reactivated as a personalized medicine and health informatics consultant for PwC.• Provide strategic support to startups, venture-backed Series A/B, Series C companies, and patient-driven nonprofits. KEY ACCOMPLISHMENTS• Connected with various companies to deliver services, including:• Vivid Genomics (San Diego, CA)• A stealth chemistry startup• A stealth gene therapy startup, and • A private genomic data company.
-
Svp, Genomic Insights And SolutionsCongenica Sep 2019 - Sep 2022Cambridge, Cambridgeshire, GbProposed and developed a new venture to leverage existing infrastructure to support pharmaceutical clients in developing genetic-driven precision medicines in rare and common diseases with a stronger probability of market success by dovetailing new discovery with identification of patients who benefit. • Implemented a revenue stream that spanned discovery research, clinical development, and post-market surveillance. • Represented the company on a global level and built partnerships in biotech/pharma, patient foundations, and academic medical centers (AMCs).KEY ACCOMPLISHMENTS• Established a new revenue path with multi-year, 6-figure contracts. • Negotiated deals with Bridge Bio, UCB, Boehringer Ingelheim, Ultragenyx, and others.• Devised an AMC partnership strategy to accelerate diagnosis by using genomics in the clinic while creating a patient data cohort to identify novel trends for the enhancement of translation to improved treatments and therapeutic R&D.• Led team in performing targeted analysis of known genes and non-targeted analysis through genome-wide association studies and validation. • Identified new targets for early onset of disease for a pharma client.• Built and led a matrixed team of 6 leaders in bioinformatics, data architecture, commercialization, marketing, and AI. -
Advisory Specialist, Precision Medicine CouncilWorld Economic Forum Aug 2018 - Aug 2022Cologny, Geneva, Ch• Advisor, Breaking Barriers to Health Data Project• Advisor, Moving Genomics into the Clinic • Advisor, Precision Medicine Readiness -
Senior Vice President & General Manager, Global Rare Disease ProgramWuxi Nextcode Genomics Dec 2017 - Jun 2019Launched a new global rare disease effort to use an existing genomic sequencing solution to accelerate diagnosis and seed new therapeutic development to advance progress benefiting the rare disease patient community. • Supervised a direct report and collaborated with bioinformatics, AI, marketing, and diagnostics teams on 3 continents. KEY ACCOMPLISHMENTS• Created a direct-to-patient sequencing reporting and data aggregation service. -
Senior Advisor, Personalized Medicine And Health InformaticsStrategy&, Part Of The Pwc Network Jun 2012 - Jun 2016Served as an expert consultant to academic and research organizations in expanding capabilities within personalized health and medicine. • Led multidisciplinary efforts to innovate operational, research, and clinical strategies to accelerate the identification of therapeutic solutions. • Handled multiple engagements involving health informatics, precision medicine, research, and clinical strategies. KEY ACCOMPLISHMENTS• Implemented IBM Watson within a leading cancer treatment center. • Advised the Glioblastoma Multiforme Think Tank and Alliance, led by a deputy director of the NCI, which was developing new treatment approaches for this aggressive cancer. • Spearheaded scientific strategy development for the National Brain Tumor Society and the Carson Leslie Foundation, nonprofits focused on brain cancer. • Served as the Chief Development and Marketing Officer for the Multiple Myeloma Research Foundation (MMRF), 2012-2013. • Implemented strategy and vision to use existing resources to translate findings into treatments.• Administered a $31.1M revenue portfolio. Restructured focus to maximize community impact through communications and outreach.• Brought in partners to identify gene drivers causing multiple myeloma, paving the way for the development of new therapies to treat the disease.
-
Director (Chief Science Officer), Systems Biology ResearchPmi Oct 2010 - Feb 2012Managed a multidisciplinary group that included 200 employees in Germany focused on in vitro and small in vivo models, pharmacology, and toxicology; 50 in Switzerland focused on bioinformatics, systems chemistry, and machine learning; and 50 in Singapore focused on large in vivo models, pharmacology, and toxicology. KEY ACCOMPLISHMENTS• Led a strategic transition to focus on systems biology approach to identify active biological molecules impacting onset of pulmonary disease, cardiovascular disease, and cancer. • With IBM as a partner, implemented initial studies to utilize supercomputers to analyze vast, disparate data sets, including genetics and genomics. Established the conceptual foundation that evolved to become IBM’s Watson.
-
President, Cell Therapeutics EuropeCell Therapeutics, Inc. Sep 2008 - Aug 2010Seattle, Wa, UsHeaded an organization that utilized a systems biology approach to position and reposition oncology therapeutics according to the genetic context of patient populations.• Hired to merge Systems Medicine, a subsidiary of CTI, into CTI Sede Secondaria to start a new company. KEY ACCOMPLISHMENTS• Established a translational medicine function to improve the probability of therapeutics’ clinical success.• Supported the development of 2 internal genetic context programs as well as traditional programs, enabling the team to make Pixantrone available in Europe on a named-patient basis. • Restructured the company’s Italian operations, handling legal/financial risk assessment, union negotiations, and contract settlements (all in Italian!). • Improved internal communications and goal alignment. -
President And Chief Operating OfficerAtyr Pharma Jan 2007 - Dec 2008San Diego, California, UsLed the creation of an R&D organization (a spinoff of The Scripps Research Institute) to develop a novel class of naturally occurring biologics for therapeutic application. • Allocated $10.5M in investments to build scientific strategy and business direction, establish laboratory facilities, and drive partnership and licensing efforts. KEY ACCOMPLISHMENTS• Established a flexible and sustainable infrastructure, intellectual property strategy, and preclinical/IND programs for advanced molecules. • Grew the company from academic collaborations to 14 FTEs.• Solidified domestic and international (Asia) partnerships. • Established the foundation of lab, operations, and strategy for the incoming CEO. -
Director, Scientific Development; Program Head, Drug Discovery; Program Manager, Drug DiscoveryGenomics Institute Of The Novartis Research Foundation Oct 2003 - Dec 2006San Diego, Ca, UsPlanned and orchestrated research and preclinical drug discovery initiatives; disease areas included oncology, metabolic, neuroscience, gastrointestinal, respiratory, infections disease, immunology, and cardiovascular. • Maintained alliances with Novartis International AG and Novartis Research in Basel, London, Singapore, and Boston. • Managed domestic and international public and scientific relations, including media communications. • Advised on due diligence activities for in-licensing and acquisition.• Reported to the Institute Director and Head of Corporate Research. KEY ACCOMPLISHMENTS• Implemented the infrastructure and processes for the drug discovery organization that produced preclinical drug candidates for Novartis. • Designed interdepartmental workflows to drive efficiency and product alignment with Novartis proper. • Advised Novartis BioVenture regarding West Coast due diligence for in-licensing and acquisitions. • Earned promotions from Program Manager (Drug Discovery Strategic Planning) to Program Head (Drug Discovery) to Director (Scientific Development).
Christina Waters, Phd Mba Skills
Christina Waters, Phd Mba Education Details
-
CaltechMolecular Biology -
University Of California, BerkeleyMolecular Biology
-
Ucla Anderson School Of ManagementGeneral
-
University Of California, DavisGenetics
-
San Diego State UniversityMolecular Biology
Frequently Asked Questions about Christina Waters, Phd Mba
What company does Christina Waters, Phd Mba work for?
Christina Waters, Phd Mba works for Archer Precision Medicine Advisory Llc
What is Christina Waters, Phd Mba's role at the current company?
Christina Waters, Phd Mba's current role is Business and Science Executive | Expert in Precision Medicine and Diagnostics, Genomics, and Rare/Common Disease | Champion for Women in STEM | Translating Science and Technology into Products that Benefit Patients.
What is Christina Waters, Phd Mba's email address?
Christina Waters, Phd Mba's email address is cw****@****nce.org
What is Christina Waters, Phd Mba's direct phone number?
Christina Waters, Phd Mba's direct phone number is +176081*****
What schools did Christina Waters, Phd Mba attend?
Christina Waters, Phd Mba attended Caltech, University Of California, Berkeley, Ucla Anderson School Of Management, University Of California, Davis, San Diego State University.
What skills is Christina Waters, Phd Mba known for?
Christina Waters, Phd Mba has skills like Drug Discovery, Biotechnology, Biomarkers, Genetics, Protein Chemistry, Strategic Planning, Pharmaceutical Industry, Leadership, Clinical Research, Strategy, Oncology, Biopharmaceuticals.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial